DPHARM 2026: The Leadership Challenge of Turning Capability into Performance
The next phase of leadership will be defined not only by how well organizations use today’s tools, but by the choices those tools make possible.
- Home
- Perspectives
- DPHARM 2026: The Leadership Challenge of Turning Capability into Performance
Clinical development continues to face familiar challenges. Protocols are becoming more complex, enrollment remains difficult, sites are undergoing operational pressure, and timelines face continued scrutiny. None of these challenges were new at DPHARM 2026.
Across planning, study delivery, workforce capability, and emerging technologies, the focus was increasingly on practical application rather than future potential.
Development organizations now have more sophisticated ways to assess feasibility, test enrollment assumptions, improve site and patient enablement, and apply emerging technologies. The challenge is no longer finding new solutions, but providing the leadership required to embed proven approaches into daily operations and translate them into better performance, lower risk, and measurable value.
Moving from Reactive to Predictive Development
Careful planning has always been critical to clinical development. However, targeted therapies, broader data requirements, complex protocols, and pressure on timelines have made study performance harder to predict.
Forecasting, modeling, and feasibility assessments allow teams to evaluate patient availability, site productivity, enrollment assumptions, and operational feasibility during planning.
Those assessments can influence site activation, enrollment targets, timelines, and resource requirements before commitments are made. More realistic assumptions can reduce timeline pressure, align site strategies with expected performance, and limit amendments and delays.
As development programs become more complex, the cost of getting critical assumptions wrong continues to rise. Better decisions before execution can support more predictable timelines, more efficient use of resources, lower avoidable costs, and accelerated patient access to new therapies.
Moving from Recruitment to Enrollment Enablement
Enrollment remains one of clinical development’s most persistent challenges. At DPHARM 2026, it was increasingly viewed as an operational challenge, not solely a recruitment challenge.
Much of that attention focused on sites. Protocol complexity, repeated training, and fragmented technology continue to pressure investigators and study teams. These factors affect activation, recruitment, retention, and execution. Standardized training, reusable qualifications, and consistent site processes can reduce duplication and allow sites to spend less time navigating requirements and more time delivering studies.
Patient participation was considered through the same operational lens. Eligibility requirements, protocol and participation burden, site readiness, infrastructure, and access pathways all influence recruitment, retention, and representation. Community-based research and patient-centered protocol design aim to address these constraints before studies launch rather than compensate for them later.
These initiatives are not new. Drug developers and CROs have invested in them for years. What is changing is how closely these activities are connected. Recruitment, retention, activation, protocol feasibility, representation, and patient access are increasingly treated as interdependent elements of study performance rather than separate workstreams.
Moving from Innovation to Demonstrated Value
For much of the last decade, discussions around AI, advanced analytics, digital measures, and other technologies focused on future potential. At DPHARM 2026, the emphasis was more practical: where these technologies improve decisions, study performance, and operational value.
AI-enabled evidence review, health record mining, predictive analytics, and advanced patient identification are being applied across clinical development.
This shifts attention to organizational capability. New technologies must be integrated into decision-making, workflows, and daily study management. Organizations need people who can evaluate outputs, challenge assumptions, and determine where technology adds value.
Many organizations will have access to similar technologies. The differentiator will be an organization’s ability to translate these technologies into measurable improvements in protocol development, patient identification, enrollment planning, evidence assessment, and study delivery.
The Next Challenge for Development Leaders
DPHARM 2026 reflected meaningful progress in how clinical development is planned and delivered. Teams can test assumptions earlier, address the connected factors influencing enrollment, and apply technologies such as AI across development.
These advances create choices beyond improving the current model. Better evidence can influence which programs progress, where resources are committed, which patient populations can be reached, and when plans should change. Connected approaches to enrollment can broaden participation, while technology can allow scarce expertise to focus on decisions that still require human judgment.
This raises expectations of development organizations. Drug developers must distinguish between complexity required by the science and complexity that adds cost without improving the study. CROs will increasingly be judged on whether their insight improves decisions before studies fall behind. Investors will have a stronger basis for assessing whether development capability supports confidence in timelines, risk, and asset value.
The opportunity is therefore larger than more predictable execution. By reducing avoidable uncertainty, organizations can direct capital, talent, and operational capacity toward the programs where they can create the greatest value. The next phase of leadership will be defined not only by how well organizations use today’s tools, but by the choices those tools make possible.
